Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) is a condition where the body's immune system mistakenly attacks the protective covering of nerves, called myelin. This can lead to muscle weakness and numbness in the arms and legs. The study is exploring if a special protein, TAK-411, can help reduce inflammation and improve symptoms in people with CIDP.
TAK-411 is a modified form of immune globulin G (hsIgG), derived from human plasma. Participants in the study may receive TAK-411 treatment for up to one year and will have follow-up visits for three additional weeks. Participants will visit the clinic up to 21 times during the study.
- Study lasts for around 54 weeks including follow-up.
- Up to 21 clinic visits are needed.
- Participants must be over 18 and have a confirmed CIDP diagnosis.
How understandable was the trial content above?
Hard to understand
Easy to understand